info@flamel.com
Company | Technologies and Products | Investor Relations | Press Releases | Contact
 
Nicolas Flamel (1330-1418)
was a French alchemist
in the Middle Ages...
learn more

Flamel Technologies is a drug delivery company with expertise in polymer chemistry.
 
The company was founded in 1990.
 
In 1996, Flamel Technologies (FLML) became the second French biotech company to enter the Nasdaq.
 
The Company has assembled a strong team of researchers expert in polymer science and biochemistry, and owns cGMP pharmaceutical production facility of over 100,000 square feet located in Pessac, France (with an annual production capacity of 2 billion tablets or capsules).
 
Flamel’s drug delivery platforms, Medusa® for therapeutic proteins and peptides, and Micropump® for small molecules , have been developed to improve the therapeutic characteristics, safety profile and ease of use of wide variety of drugs.
 
The Company is a recognized world leader in the innovation of delivery systems for small molecule and protein drugs, providing tailored solutions to the biotech and pharmaceutical industries for optimized controlled-release delivery of drugs. Flamel is turning already-marketed or new drugs into more effective and safer medicines for itself and for its partners.
 
Flamel has partnership agreements with major pharmaceutical companies.
 
The Company is actively seeking partnership agreements for the development and commercialization of products currently in its pipeline as well as for new products using Flamel’s proprietary delivery systems.

Flamel Technologies Presentation - August 6, 2008
To view the latest presentation, click here.

Second Quarter 2008 Earnings Announcement:
 Flamel released its earnings announcement for the second quarter on August 6th after the market close.
A conference call to discuss these results is scheduled for 8:30 AM (EDT)
August 07, 2008.
The dial-in number is (1) 800-374-1498.
International callers are invited to dial-in (1) 706-634-7261.
The Conference ID number is 57373983.
Conference Call Webcast
press release

On April 25, 2008, Flamel Technologies announced the presentation of results of two week study of interferon alpha XL at the European Association for the Study of the Liver.
Click here to access the presentation entitled "Antiviral activity and tolerance of a novel interferon-alpha-2b sustained release(IFN-alpha-2bXL) compared to Peg-IFN-alpha-2b:a phase Ib trial in HCV patients".

 
Latest News Medusa ® Micropump ® Technologies

August 6, 2008
Flamel Technologies Announces Second Quarter Results and New Medusa Contracts
A conference call to discuss earnings is scheduled for 8:30 AM EDT August 7, 2008.
The dial-in number (for investors in the U.S. and Canada) is 1-800-374-1498; the conference ID number is 57373983.
International investors are invited to dial 1-706-634-7261.
Conference Call Webcast

July 23, 2008
Flamel Technologies Announces Projected Release Date of Second Quarter 2008 Results, Conference Call

June 03, 2008
Flamel Technologies Announces Results of Annual Meeting

May 13, 2008
Flamel Technologies Announces First Quarter Results, Milestone Payment, and Trigger Lock Feasibility Agreement

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info
 
Micropump® and Medusa® are registered trademarks of Flamel Technologies S.A.
Copyrights © 2008 Flamel Technologies S.A. All rights reserved